Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial

28 May 2018 (14:45 - 14:51)
Organised by:
Congress Presentation Part of: Patient management - From oral treatment to transplant Diabetes and the Heart HFA Premium Access Heart Failure 2018